The Latest Breaking News from Novavax

Experts hope the new COVID vaccine, which uses older biotechnology, could help the unvaccinated come around

The Food and Drug Administration voiced concern Friday about myocarditis being potentially linked to the Novavax Covid-19 vaccine, just as experts are to weigh its use in the United States. The Novavax vaccine is already authorized in other countries, particularly in Europe. In the United States, an independent committee convened…

Novavax evaluation comes days before key FDA meeting

The FDA suggested Friday there could be a link between Novavax's Covid vaccine and heart inflammation, and NVAX stock plummeted.

Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its COVID-19 vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 9.78% on an annualized basis producing an average annual return of 19.75%. Currently, Novavax has a market capitalization of $3.69 billion.

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 14.20% at $50.14. Bank of America's Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.

Someone with a lot of money to spend has taken a bullish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Although Novavax, Inc’s (NASDAQ: NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities. The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.

Upgrades